Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770155 | 0.87 | ACE (0.54) | ACENAALAD2MMECPA1 | |
| SCHEMBL1081372 | 0.82 | FOLH1 (0.54) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL31533361 | 0.82 | FOLH1 (0.54) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL1081373 | 0.82 | FOLH1 (0.54) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL31533362 | 0.82 | FOLH1 (0.54) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL8823272 | 0.81 | ACE (0.58) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL8823270 | 0.81 | ACE (0.58) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL10778599 | 0.80 | FOLH1 (0.55) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL8414223 | 0.80 | FOLH1 (0.55) | ACEFOLH1NAALAD2SLC7A5MME | |
| SCHEMBL148423 | 0.80 | FOLH1 (0.55) | ACEFOLH1NAALAD2SLC7A5MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794492-B2 | N-(2,2,2-TRIFLUOROETHYL)GLYCINE DERIVATIVES; CAN BE USED TO PREPARE LIPOPHILIC PROTEINS ADAPTED FOR CROSSING THE BLOOD BRAIN BARRIER | CLEMSON UNIVERSITY | 2004-09-21 | — | — | US | claimed |
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2019-02-21 | — | — | US | disclosed |
| WO-2017075522-A2 | GLP-2 POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075505-A2 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | TUFTS UNIVERSITY (US) | 2017-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055279-A1 | NOVEL POLYPEPTIDES WITH IMPROVED PROTEOLYTIC STABILITY, AND METHODS OF PREPARING AND USING SAME | PTMS, ANPEP, DNPEP | ACE 441/4885FOLH1 211/4885NAALAD2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.